Pharmamarketeer

US FDA approves AbbVie’s oral JAK inhibitor, Rinvoq to treat rheumatoid arthritis

AbbVie, a research─based global bio pharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a 15 mg, once─daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA)

Advertentie(s)